| __timestamp | HUTCHMED (China) Limited | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 72049000 | 18516000 |
| Thursday, January 1, 2015 | 110777000 | 34140000 |
| Friday, January 1, 2016 | 156328000 | 51872000 |
| Sunday, January 1, 2017 | 175820000 | 71772000 |
| Monday, January 1, 2018 | 143944000 | 97501000 |
| Tuesday, January 1, 2019 | 160152000 | 118590000 |
| Wednesday, January 1, 2020 | 188519000 | 169802000 |
| Friday, January 1, 2021 | 258234000 | 7491000 |
| Saturday, January 1, 2022 | 311103000 | 8799000 |
| Sunday, January 1, 2023 | 384447000 | 253598000 |
Unleashing insights
In the ever-evolving landscape of the pharmaceutical and biotechnology sectors, understanding cost structures is crucial. HUTCHMED (China) Limited and Xencor, Inc. offer a fascinating comparison. Over the past decade, HUTCHMED's cost of revenue has surged by over 430%, from approximately $72 million in 2014 to nearly $384 million in 2023. This growth reflects their expanding operations and market reach. In contrast, Xencor, Inc. experienced a more volatile trajectory, with costs peaking at around $254 million in 2023, a significant leap from just $7 million in 2021. This fluctuation highlights the dynamic nature of biotech investments and the challenges of scaling operations. As these companies navigate the complexities of their industries, their cost of revenue trends provide valuable insights into their strategic priorities and market positioning.
Analyzing Cost of Revenue: Eli Lilly and Company and Xencor, Inc.
Cost of Revenue Trends: AbbVie Inc. vs Xencor, Inc.
Cost Insights: Breaking Down AstraZeneca PLC and Xencor, Inc.'s Expenses
Cost of Revenue Comparison: Incyte Corporation vs HUTCHMED (China) Limited
Cost of Revenue Comparison: Intra-Cellular Therapies, Inc. vs HUTCHMED (China) Limited
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and HUTCHMED (China) Limited
Cost of Revenue Comparison: Cytokinetics, Incorporated vs HUTCHMED (China) Limited
Analyzing Cost of Revenue: Amneal Pharmaceuticals, Inc. and HUTCHMED (China) Limited
Cost of Revenue: Key Insights for CRISPR Therapeutics AG and HUTCHMED (China) Limited
Bausch Health Companies Inc. vs HUTCHMED (China) Limited: Efficiency in Cost of Revenue Explored
Research and Development Investment: HUTCHMED (China) Limited vs Xencor, Inc.
Cost of Revenue: Key Insights for BioCryst Pharmaceuticals, Inc. and Xencor, Inc.